AI Investor Forum: Gus Tai on AI in Healthcare (Part 4)

Sramana Mitra: Yes. On the process side, we’ve had a company become quite successful in the program. It is bootstrapped. We looked at raising money, but eventually, it was going fine as a bootstrapped company. I think it continues to bootstrap. It’s called CliniOps.

AI Investor Forum: Gus Tai on AI in Healthcare (Part 3)

Sramana Mitra: Now, let’s shift to medical imaging, which is another area where AI is having lots of impact. There are lots of companies working in this field, and lots of entrepreneurial efforts going on in this field. The question that I’m of thinking about is that, are these going to be unicorn style opportunities?

AI Investor Forum: Gus Tai on AI in Healthcare (Part 1)

Gus Tai, Investor, Board Member and Retired General Partner at Trinity Ventures, discusses AI in Healthcare startups. Fascinating, comprehensive discussion with concrete pointers.

666th 1Mby1M Entrepreneurship Podcast with Investor Gus Tai (Part 3, 2024)

Gus Tai, Investor, Board Member and Retired General Partner at Trinity Ventures, discusses AI in Healthcare startups. Fascinating, comprehensive discussion with concrete pointers.

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 7)

Sramana Mitra: In a fifteen-year span, the early venture guys are trying to go to $100 million in revenue and commensurate valuation in five to seven years. So, if they want to cash out the fact that you’re staying private in 15 years, that means that there is going to be some amount of change

Read Full Article »

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 6)

Sramana Mitra: That means architecturally, you’re going to put a recording and transcription agent on the iPad, this is not happening on the cloud, right? Daniel Cane: Right. There are several reasons for this approach. First and foremost, it’s about performance and latency. By keeping everything on the device, we’re minimizing the amount of information

Read Full Article »

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 3)

Sramana Mitra: I purposely actually picked to highlight the positioning points where you can differentiate it versus areas where you cannot really differentiate. The domain of billing is less of a big differentiation in ModMed. The bigger differentiation is in the specialty specific content, specialty specific workflow and specialty specific treatment, right?

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 1)

I first spoke with Dan a decade back. Here is the story. This conversation offers insights on his scaling strategy with ModMed.